Dermal Enhancement: Bacterial Products on Intact Skin Induce and Augment Organ-Specific Autoimmune Disease

Journal of Immunology

Volumn 172, Issue 1, 2004, Pages 302-309

  Riminton, D Sean ^b   Kandasamy, Rama ^b   Dravec, Danijela ^b   Basten, Antony ^b   Baxter, Alan G ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CHOLERA TOXIN; GAMMA INTERFERON; INSULIN; INSULIN B PEPTIDE [9-23]; INTERLEUKIN 4; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN [35-55]; PEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATING DISEASE; DIABETES MELLITUS; HOST RESISTANCE; INSULITIS; MOUSE; NONHUMAN; PANCREAS ISLET; PARALYSIS; PRIORITY JOURNAL; SKIN; T LYMPHOCYTE; VACCINATION;

EID: 0346734187     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.1.302     Document Type: Article

References (32)

1. Glenn, G. M., M. Rao, G. R. Matyas, and C. R. Alving. 1998. Skin immunization made possible by cholera toxin. Nature 391:851.
2. Glenn, G. M., T. Scharton-Kersten, R. Vassell, C. P. Mallett, T. L. Hale, and C. R. Alving. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161:3211.
3. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6:1403.
4. Guerena-Burgueno, F., E. R. Hall, D. N. Taylor, F. J. Cassels, D. A. Scott, M. K. Wolf, Z. J. Roberts, G. V. Nesterova, C. R. Alving, and G. M. Glenn. 2002. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70:1874.
5. Arrington, J., R. P. Braun, L. Dong, D. H. Fuller, M. D. Macklin, S. W. Umlauf, S. J. Wagner, M. S. Wu, L. G. Payne, and J. R. Haynes. 2002. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J. Virol. 76:4536.
6. Riminton, D. S., H. Körner, D. H. Strickland, F. A. Lemckert, J. D. Pollard, and J. D. Sedgwick. 1998. Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice. J. Exp. Med. 187:1517.
7. Gardinier, M. V., P. Amiguet, C. Linington, and J. M. Matthieu. 1992. Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily. J. Neurosci. Res. 33:177.
8. Daniel, D., and D. R. Wegmann. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 93:956.
9. - (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 187:1047.
10. Tomonari, K. 1998. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 28:455.
11. Bernard, C. C., and P. R. Carnegie. 1975. Experimental autoimmune encephalomyelitis in mice: immunologic response to mouse spinal cord and myelin basic proteins. J. Immunol. 114:1537.
12. Lycke, N., and J. Holmgrem. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301.
13. Glenn, G., T. Scharton-Kersten, R. Vassell, G. R. Matyas, and C. A. Alving. 1999. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67:1100.
14. Lycke, N., A. K. Bromander, L. Ekman, U. Karlsson, and J. Holmgren. 1989. Cellular basis of immunomodulation by cholera toxin in vitro with possible association to the adjuvant function in vivo. J. Immunol. 142:20.
15. Bromander, A., J. Holmgren, and N. Lycke. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J. Immunol. 146:2908.
16. Hornquist, E., and N. Lycke. 1993. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 23:2136.
17. Li, T. K., and B. S. Fox. 1996. Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone. Int. Immunol. 8:1849.
18. Sadelain, M. W., H. Y. Qin, J. Lauzon, and B. Singh. 1990. Prevention of type 1 diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39:583.
19. Sai, P., and A. S. Rivereau. 1996. Prevention of diabetes in the nonobese diabetic mouse by oral immunological treatments: comparative efficiency of human insulin and two bacterial antigens, lipopolysacharide from Escherichia coli and glycoprotein extract from Klebsiella pneumoniae. Diabetes Metab. 22:341.
20. Quintana, F. J., A. Rotem, P. Carmi, and I. R. Cohen. 2000. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J. Immunol. 165:6148.
21. Coon, B., L. L. An, J. L. Whitton, and M. G. von Herrath. 1999. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104:189.
22. Sun, J. B., B. G. Xiao, M. Lindblad, B. L. Li, H. Link, C. Czerkinsky, and J. Holmgren. 2000. Oral administration of cholera toxin B subunit conjugated to myelin basic protein protects against experimental autoimmune encephalomyelitis by inducing transforming growth factor-β-secreting cells and suppressing chemokine expression. Int. Immunol. 12:1449.
23. Bergerot, I., C. Ploix, J. Petersen, V. Moulin, C. Rask, N. Fabien, M. Lindblad, A. Mayer, C. Czerkinsky, J. Holmgren, and C. Thivolet. 1997. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl. Acad. Sci. USA 94:4610.
24. Braun, M. C., J. He, C. Y. Wu, and B. L. Kelsall. 1999. Cholera toxin suppresses interleukin (IL)-I2 production and IL-12 receptor β1 and β2 chain expression. J. Exp. Med. 189:541.
25. + regulatory T-cells. Diabetes 48:2150.
26. Homquist, E., and N. Lycke. 1995. Cholera toxin increases T lymphocyte responses to unrelated antigens. Adv. Exp. Med. Biol. 371B:1507.
27. Serreze, D. V., H. D. Chapman, C. M. Post, E. A. Johnson, W. L. Suarez-Pinzon, and A. Rabinovitch. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166:1352.
28. Freund, J., E. R. Stem, and T. M. Pisani. 1947. Isoallergic encephalomyelitis and radiculitis in guinea pigs after one injection of brain and mycobacteria in water-in-oil emulsion. J. Immunol. 57:179.
29. Scharton-Kersten, T. J. Yu, R. Vassell, D. O'Hagan, C. R. Alving, and G. M. Glenn. 2000. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68:306.
30. Freytag, L. C., and J. D. Clements. 1999. Bacterial toxins as mucosal adjuvants. Curr. Top. Microbiol. Immunol. 236:215.
31. Ichikawa, H. T., L. P. Williams, and B. M. Segal. 2002. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J. Immunol. 169:2781.
32. Elson, C. O. 1992. Cholera toxin as a mucosal adjuvant: effects of H-2 major histocompatibility complex and lps genes. Infect. Immun. 60:2874.